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Summary A prospective study was performed to evaluate the feasibility of full dose chemotherapy given on
schedule in elderly patients with unfavourable non-Hodgkin's lymphoma, stage E, III and IV. Using a
combination regimen of six courses of cyclophosphamide, mitoxantrone, vincristine and prednisone (CNOP)
given every 4 weeks, no serious toxicity was encountered in a group of 30 consecutive patients with a mean age
of 70.4 years. A 60% complete response rate was observed and a total response rate of 90%. The disease-free
survival of complete responders was 50% at 1 year. The overall survival was also 50% at 1 year. In 148
courses of CNOP only two serious infectious episodes were noted, i.e. one herpes zoster infection and one case
of bronchopneumonia. Asymptomatic transient thrombocytopenia and granulocytopenia were commonly
observed. Nadirs of white blood cells were WHO grade 1, 2, 3 and 4 in six, five, twelve and two patients
respectively and nadirs of thrombocytopenia were WHO grade 0 and 1 (22 patients) or 2 (three patients).
Based on low white blood cell counts, a delay of I week before administration of the next course of CNOP
was necessary in 7% of the courses. No dose reductions were applied. Toxicity other than transient
granulocytopenia was minor and consisted of alopecia and nausea, WHO grade 0-2. CNOP related toxicity
was never a reason to stop treatment. It is concluded that CNOP chemotherapy without initial dose reduction
in elderly patients wtih intermediate and high grade malignant non-Hodgkin's lymphoma is feasible and that
no major toxicity is observed.
In elderly patients with unfavourable non-Hodgkin's lym-
phoma with extensive disease CHOP (cyclophosphamide, vin-
cristine, doxorubicin, prednisone) chemotherapy is often the
treatment of choice, since there is at present a scarcity of
follow-up data showing a therapeutic advantage of more
intensive regimens. In a study of diffuse histiocytic lymphoma
in elderly patients it was shown that the initial dose of
doxorubicin and/or cyclophosphamide in CHOP-like regi-
mens is often reduced (Dixon et al., 1986). The decision to
reduce the dose ofcytostatic drugs in this group ofpatients is
generally based on their age only, even if concomitant disease
is not present. However, not all studies show that age is an
independent prognostic factor and among other causes re-
duced drug doses may contribute to the poorer survival of
elderly patients in these studies (Jagannath et al., 1985;
O'Connell et al., 1986; Dixon et al., 1986).
The present study was initiated to test the feasibility of
such a strategy. Doxorubicin is a major drug in most regi-
mens for non-Hodgkin's lymphoma, and in the CHOP regi-
men it may contribute to cardiac morbidity, which was the
second cause of death in a study on treatment of NHL in the
elderly (Armitage & Potter, 1984). Mitoxantrone is a DNA
intercalating drug with less cardiotoxicity than doxorubicin,
while being equally effective in malignant lymphoma (Dansey
& Bezwoda, 1987). Therefore we decided to combine mitox-
antrone with cyclophosphamide, vincristine and prednisone
(CNOP) to test the feasibility of full dose chemotherapy in
elderly patients with non-Hodgkin's lymphoma.
Patients and methods
Patients
Thirty consecutive eligible patients (nine male, 21 female),
aged 57-83 years (mean 70.4) with untreated intermediate or
high grade malignant non-Hodgkin's lymphoma (NHL)
(n = 28) or with low grade malignant NHL with bulky
disease (n = 2) not responding to previous chemotherapy
were enrolled in the CNOP study. We considered all individ-
uals above 60 years of age as elderly patients, since age above
60 years is an exclusion criterion in all ongoing national and
EORTC trials for adults with malignant lymphoma. Two
patients below 60 years were included because concomitant
heart disease made them ineligible for other treatment pro-
tocols. All patients were staged by routine blood examina-
tion, chest roentgenography, computerised tomography of
abdomen and computerised tomography ofthe thorax in case
of abnormal chest roentgenography, bone marrow puncture
and/or biopsy.
The median follow-up of all patients was 16 months (range
3-38 months). The median follow-up ofcomplete responders
was 24 months (range 5-38 months).
Methods
Malignant non-Hodgkin's lymphoma was diagnosed accord-
ing to the working Formulation and the Ann Arbor
classification (National Cancer Institute, 1982). All patients
had a performance status according to the scale of the World
Health Organization (WHO) grade 0-2. In patients with a
history of cardiac illness a left ventricular ejection scan was
made before and at the end of treatment. Immunophenotyp-
ing using monoclonal antibodies was performed on biopsies
obtained from pathologic lymph nodes and/or bone marrow
and from liver biopsies when indicated. The results of his-
topathological classification, clinical staging and response to
CNOP chemotherapy are shown in Table I. The NHLs were
classified as follicular predominantly large cell (centroblastic)
in two patients, diffuse small cleaved (centrocytic) in two
patients, diffuse mixed small and large cell (centrocytic/cen-
troblastic) in five patients, diffuse large cell (centroblastic) in
16 and diffuse large cell immunoblastic in five patients.
All patients had extensive disease (stage III and IV) or
significant extranodal organ involvement, although clinically
stage 1E.
Treatment
No patient had received prior or concomitant radiotherapy,
while two patients were refractory to six courses of chemo-
therapy (cyclophosphamide, vincristine, prednisone). The
CNOP chemotherapy regimen consisted of six courses of
cyclophosphamide (750 mgm-2, i.v. day 1), mitoxantrone
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(10 mg m-2, i.v. day 1), vincristine (1.4 mg m-2, i.v. day 1)
and prednisone (50 mg m-2 p.o. days 1-5), at 4 weeks inter-
val. Following the first course, which was administered dur-
ing a brief hospital stay, the peripheral blood haemoglobin
content, the leukocyte count and differentials and the platelet
count were determined bi-weekly in 25 patients. The toxicity
of the treatment was assessed according to the WHO guide-
lines.
Complete response was defined as complete disappearance
of all disease related symptoms, normalisation of all tests and
absence of roentgenologic abnormalities. Partial response was
defined as decrease by at least 50% of all measurable patho-
logical lymphomas and more than 25% decrease of liver and
spleen enlargement with normalisation of laboratory tests
and bone marrow smear, while no new lesions should occur.
Results
the total number of responders was 27 (90%). The overall
survival and the disease-free survival of patients in complete
remissions are given in Figure 1. At present there are nine
patients surviving more than 2 years, with a median follow-
up of 23 months.
Toxicity
Frequent haematological surveillance following the first
course of CNOP showed that asymptomatic thrombocyto-
penia and leukocytopenia, in particular granulocytopenia,
were commonly observed at days 10-14 following treatment
(Table II). However, in 148 courses of CNOP in 30 patients
only two serious infectious episodes were encountered, i.e.
one herpes zoster infection and one paronychia combined
with bronchopneumonia, for which short clinical admissions
and antibiotic therapy were needed. A delay of 1 week before
administration of the next course of CNOP was necessary in
less than 7% of the courses. No dose reduction was applied
Efficacy
At the time of evaluation therapy had generally consisted of
five or six courses of CNOP. However, CNOP courses were
stopped because of progressive disease in three patients and
in case of not attaining a complete response after three
courses of CNOP in five patients. CNOP related toxicity was
never a reason to stop treatment. Two patients received two
additional courses of CNOP to a total of eight courses
because of initial bulky disease. Table I lists the results of
treatment with CNOP chemotherapy as well as the number
of courses needed to obtain the clinical response. Eighteen
out of 30 patients (60%) attained a complete remission, while
Table II Toxicity of the CNOP regimen in
according to WHO criteria
30 elderly patients
Grade 0+ I Grade 2 Grade 3 Grade 4
Alopecia 16 10 4 0
Nausea/vomiting 25 5 0 0
Neurotoxicity 28 2 0 0
Infections 28 2 0 0
Cardiac toxicity 0 0 0 0
Liver toxicity 0 0 0 0
Platelets 25 3 0 0
White blood cells 6 5 12 2




Patient Age Stagea PS6 Sex courses Responsec courses (no.) Remarks
1 71 A, IIIB 0 F 5 CR 2
2 58 A, IIIA I M 5 CR 2
3 68 D, IVB 0 F 6 PR 3
4 67 D, IVA 0 F 6 CR 3
5 65 B, IIIA 0 M 6 CR 3
6 61 C, IIIA I F 3 PR 3
7 73 C, IVA 2 F 6 CR 3
8 69 C, IE I F 3 PR 3
9 80 D, IIIA 2 F 6 PR 3
10 66 D, IVB 2 M 3 NR -
I1 73 E, IE 0 F 6 CR 3
12 76 D, IIIA 1 F 1 CR 1 Lost to
follow-up
13 69 C, IVA 2 F 6 CR 6
14 57 E, IE 0 M 5 CR 3
15 67 D, IIIA I F 6 CR 6 Relapse
treatment
16 66 D, IVB 2 F 6 CR 6 Relapse
treatment
17 73 D, IVA 1 M 6 CR 3
18 62 D, IE 1 F 6 CR 3
19 67 D, IIIB 1 M 3 PR 3
20 77 E, IVA 1 F 8 CR 6
21 78 D, IVA 1 M 3 PR 3
22 73 D, IIIA 2 F 3 NR -
23 77 C, IIIA 0 F 6 PR 3
24 73 D, IVA 1 M 3 PR 3
25 74 E, IVA 1 F 7 CR 3
26 65 D, IIIA 1 F 3 NR -
27 66 D, IVB 0 F 8 CR 3
28 70 D, IVB 0 F 5 CR 3
29 86 B, IVA 0 F 2 PR 2
30 77 E, IVA I M 6 CR 3
aMorphology according to Working Formulation: A, follicular, predominantly large cell; B, diffuse small
cleaved; C,mixed smalland largecell; D,diffuselargecell; E, largecellimmunoblastic. StageaccordingtoAnn
Arbor classification. bPS, performance status according to WHO. CCR, complete response; PR, partial
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Figure 1 Kaplan Meier survival of patients treated with CNOP.
in these patients. Toxicity other than granulocytopenia was
minor. Table II gives the maximal WHO toxicity score
encountered in each patient during successive courses of
CNOP. Unacceptable toxicity did not occur. In six patients
with a history of cardiac illness who could be evaluated after
five or six courses of CNOP a left ventricular ejection was
performed before and after completing therapy. These pa-
tients all had a pretreatment left ventricular ejection fraction
of 40-70%. No significant reduction of the ventricular out-
put following CNOP therapy was noted in any patient.
Discussion
Advanced non-Hodgkin's lymphoma of intermediate or high
grade malignancy not restricted to a single site is usually
treated with combination chemotherapy. Complete response
rates of stage II-IV unfavourable NHL ranging from 40 to
80% can be achieved using anthracycline-containing regi-
mens like ProMaceMOPP (Fisher et al., 1983), M-BACOD
(Skarin et al., 1983), COP-BLAM (Laurence et al., 1982),
MACOP-B (Klimo & Connors, 1987) and CHOP (Armitage
et al., 1986). In these studies a high complete response rate is
associated with improved survival. The toxicity of these
regimens is, however, considerable and a significant number
of elderly patients may not complete the required number of
chemotherapy courses (Connors, 1988), due to a poor perfor-
mance status and/or considerable therapy-related morbidity
(Anderson et al., 1982; Goh & Williams, 1983; Armitage &
Potter, 1984; Mead et al., 1984; O'Connell et al., 1986).
Several studies have found a poorer prognosis of un-
favourable NHL in elderly patients when compared to their
younger counterparts (Jagannath et al., 1985; Solal-Celigny
et al., 1987; Fisher et al., 1987; Dixon et al., 1986). Among
other causes, such a difference of response may be related to
less intensive treatment due to initial dose reductions of the
drugs administered to elderly patients (Boyd et al., 1988).
Therefore it may be expected that full dose chemotherapy
given on schedule will lead to better complete response rates
in elderly patients, provided that the toxicity of such an
approach is acceptable (O'Connell et al., 1986; Dixon et al.,
1986). In CHOP-like regimens the initial dose of doxorubicin
was frequently reduced because of expected toxicity (Dixon
et al., 1986). If doxorubicin is replaced by mitoxantrone, a
less toxic anthraquinone drug, full dose chemotherapy may
be better tolerated by elderly patients with extensive non-
Hodgkin's lymphoma.
There is no direct comparison of the efficacy of doxo-
rubicin alone and mitoxantrone alone in elderly patients with
untreated lymphoma. In a study by Brusamolino, comparing
CNOP and CHOP in lymphoma patients not selected for
age, mitoxantrone at a dose of 12 mg m 2 was given (Dansey
& Bezwoda, 1987; Brusamolino et al., 1988). They observed a
lower leucocyte nadir in the CNOP treated patients. In
another study M-BACOD was compared with the identical
regimen except for the exchange of mitoxantrone at
10 mg m2 for doxorubicin, where no therapeutic difference
was found in a population with NHL not selected for age
(Case et al., 1988). In a similar fashion mitoxantrone at a
dose of 10mgm2 was selected for the present study.
A response rate of 90% with 60% complete responses was
obtained without significant adverse side-effects. In those
patients who completed five or more courses of CNOP the
complete response rate was 80%. These results are comparable
with or even better than the complete response rates published
by Dixon et al. (1986) for the same age group treated with
CHOP. The disease-free and overall survival is somewhat less
than in younger patients receiving CNOP (Brusamolino et al.,
1988) (50 vs 70%). However, the relapse-free survival at 2 years
is comparable with that of elderly patients in previously
published studiesusingCHOP(Armitage&Potter, 1984; Dixon
et al., 1986). Thus, CNOP appears to be a good alternative to
doxorubicin-containing regimens. This was further determined
by two studies comparing CNOP with CHOP in a group of
patients not selected for age, in which no therapeutic difference
wasfound (Dansey&Bezwoda, 1987; Brusamolino etal., 1988).
Based on these results we have now started a prospective
randomised clinical study in patients over 60 years ofage with
unfavourable NHL, to compare full dose CNOP versus CHOP
with respect to toxicity, response rate and survival.
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